New laboratory biomarkers of rheumatoid arthritis

Dibrov, D. A.

doi:10.47360/1995-4484-2021-201-207

Naučno-praktičeskaâ revmatologiâ

2021

DOI: 10.47360/1995-4484-2021-201-207

|View full text |Cite

New laboratory biomarkers of rheumatoid arthritis

D. A. Dibrov¹

Abstract: The review presents data on new biomarkers for the diagnosis of rheumatoid arthritis, considers the diagnostic parameters of antibodies to carbamylated proteins, antibodies to peptidyl arginine deaminase, antibodies to homocysteinylated α1-antitrypsin, 14-3-3η, macrophage soluble scavenger receptor A. The use of new biomarkers can improve the diagnosis of RA in the early stages, as well as stratify patients based on the prognosis of the disease and provide a rational selection of therapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article3

Relationship

Self Cite2

Independent1

Authors

Journals

Cited by 3 publications

References 87 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Anti-Carbamylated Protein Antibodies in ACPA-Negative and ACPA-Positive Patients with Rheumatoid Arthritis

Dibrov,

Avdeeva,

Diatroptov

et al. 2024

Dokl Biochem Biophys

View full text Add to dashboard Cite

Anti-Carbamylated Protein Antibodies in ACPA-Negative and ACPA-Positive Patients with Rheumatoid Arthritis

Dibrov,

Avdeeva,

Diatroptov

et al. 2024

Dokl Biochem Biophys

View full text Add to dashboard Cite

ACCP-negative rheumatoid arthritis – clinical and immunological features

Dibrov¹

2022

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

Depending on the presence of laboratory biomarkers: rheumatoid factor IgM and anti-cyclic citrullinated peptide antibodies (ACCP), “seropositive” and “seronegative” variants of rheumatoid arthritis (RA) are distinguished. Immunological subtypes differ in risk factors, immunopathogenesis, and the course of the disease. A review of data concerning immunology and clinical features of ACCP-negative rheumatoid arthritis is presented. The presence of ACCP in the peripheral blood reflects the progressive erosive process with a predominance of the inflammatory component and involvement of the B cells. Proliferative changes predominate in the ACCPnegative subtype; disorders associated with the T-cell link, primarily with CD4+ T-lymphocytes, play an important role in pathogenesis. This variant of the disease is characterized by a less pronounced erosive process, but the inflammatory activity in both subtypes of RA can be comparable. Early diagnosis, regular monitoring of the disease activity and the «treat to target» strategy are recommended for both positive and negative ACCP RA, however, the effectiveness of individual drugs in these subtypes may vary significantly.

show abstract

Anti-carbamylated protein antibodies in ACCP-negative and ACCP-positive patients with rheumatoid arthritis

Dibrov,

Avdeeva,

Diatroptov

et al. 2024

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

Objective. Assess the level of antibodies to carbamylated proteins (anti-CarP) and analyse the clinical and immunological associations in patients with ACCP-negative and ACCP-positive variants of rheumatoid arthritis.Materials and methods. 150 patients with a reliable diagnosis of rheumatoid arthritis and 25 patients as healthy controls were included in the study. Depending on ACCP values, two groups of patients were recruited: ACCP-positive (n=75) and ACCP-negative (n=75). RA activity was assessed by the DAS28 (Disease Activity Score 28) index. Determination of antibodies to carbamylated proteins was performed by enzyme-linked immunosorbent assay (BlueGene Biotech, China). Quantitative determination of ACCP in serum was performed by enzyme immunoassay using a commercial reagent kit (AxisShield, UK; upper limit of normal 5.0 U/ml; Orgentec, Germany; upper limit of normal 20.0 U/ml).Results and discussion. Me for anti-CarP in patients with RA was 126.2 [100.83; 157.41] ng/ml and was statistically significantly higher (p<0.001) than healthy controls 88.89 [70.53; 107.75] ng/ml. Among all patients with RA, 50 (33.3%) were anti-Carp positive, 22 (29.3%) were anti-Carp(+) in the ACCP(+) group, 28 (37.3%) in the ACCP(–) group, and 1 (2%) volunteer from healthy controls (p=0.002). In ROC analysis to assess the diagnostic significance of anti-Carp for RA for all patients with RA, the area under the curve was 0.783±0.047 (95% CI: 0.691–0.874; p<0.001), with a cut-off point of 143 ng/ml, specificity 96%, sensitivity 36.7%.In the ACCP(+) RA group, the erosion count was statistically significantly higher (p=0.044) in anti-CarP(+) patients than in anti-CarP(–) patients. A weak direct correlation between anti-CarP and DAS28 was found in the ACCP(–) RA group.Conclusion. We studied the predictive value of anti-CarP as an adjuvant biomarker in ACCP(+) and ACCP(–) subtypes of RA. ACCP(+), anti-CarP(+) patients have a more “erosive” subtype of the disease than ACCP(+), anti-CarP(–) patients. In ACCP(+) patients, anti-CarP helps to identify a more erosive subtype of the disease, and among ACCP(–) patients, it helps to reduce the proportion of seronegative patients. Further studies are needed to determine the optimal standards for the laboratory diagnosis of anti-CarP and to clarify the diagnostic potential of these antibodies as part of the differential diagnosis of arthritis in other rheumatic diseases.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

New laboratory biomarkers of rheumatoid arthritis

Cited by 3 publications

References 87 publications

Anti-Carbamylated Protein Antibodies in ACPA-Negative and ACPA-Positive Patients with Rheumatoid Arthritis

Anti-Carbamylated Protein Antibodies in ACPA-Negative and ACPA-Positive Patients with Rheumatoid Arthritis

ACCP-negative rheumatoid arthritis – clinical and immunological features

Anti-carbamylated protein antibodies in ACCP-negative and ACCP-positive patients with rheumatoid arthritis

Contact Info

Product

Resources

About